Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)
Taiwan
· Delayed Price · Currency is TWD 28.65
+0.30 (1.05%)
Jun 6, 2025, 1:35 PM CST
TPE:1762 Revenue
Chunghwa Chemical Synthesis & Biotech had revenue of 192.95M TWD in the quarter ending March 31, 2025, a decrease of -23.34%. This brings the company's revenue in the last twelve months to 1.29B, down -18.06% year-over-year. In the year 2024, Chunghwa Chemical Synthesis & Biotech had annual revenue of 1.35B, down -35.42%.
Revenue (ttm)
1.29B
Revenue Growth
-18.06%
P/S Ratio
1.72
Revenue / Employee
6.51M
Employees
198
Market Cap
2.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.35B | -739.07M | -35.42% |
| Dec 31, 2023 | 2.09B | -30.70M | -1.45% |
| Dec 31, 2022 | 2.12B | 182.44M | 9.43% |
| Dec 31, 2021 | 1.93B | 391.11M | 25.34% |
| Dec 31, 2020 | 1.54B | 386.95M | 33.45% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 11.34B |
| Caliway Biopharmaceuticals | 40.47M |
| Bora Pharmaceuticals Co., LTD. | 20.87B |
| Lotus Pharmaceutical | 19.12B |
| Polaris Group | 87.67M |
| Lumosa Therapeutics | 43.59M |
| Center Laboratories | 1.63B |
| Oneness Biotech | 117.33M |